We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 211

Announcement of Cover Florida participating health insurance companies delayed

  • Locke Lord LLP
  • -
  • USA
  • -
  • October 8 2008

Last August, Florida Governor Charlie Crist announced that nine health insurers submitted insurance coverage plans to provide healthcare insurance under the Cover Florida plan

House passes revised bailout bill

  • Locke Lord LLP
  • -
  • USA
  • -
  • October 6 2008

Last Friday, the House of Representatives passed the Senate’s revised version of the $700 billion bailout bill, H.R. 1424, by a vote of 263-171

Insurer to exclude nanotube and nanotechology from coverage

  • Locke Lord LLP
  • -
  • USA
  • -
  • October 15 2008

On October 2, 2008, Advisen reported that insurance company Continental Western Group (“CWG”) announced that it would exclude nanotube and nanotechnology from its coverage

UnitedHealthcare settles claims for $12 million

  • Locke Lord LLP
  • -
  • USA
  • -
  • October 23 2007

UnitedHealthcare, a subsidiary of UnitedHealth Group, Inc., entered into a settlement agreement last month whereby it agreed to pay $12 million to the Attorneys General of 36 states and the District of Columbia

New York to create new workers’ compensation medical treatment regulations

  • Locke Lord LLP
  • -
  • USA
  • -
  • December 7 2007

New York Superintendent of Insurance Eric R. Dinallo has asked the State’s Workers’ Compensation Board to create new regulations for workers’ compensation medical treatment using recently issued evidence-based guidelines

When rescission is proper: California appellate court takes on postclaims underwriting in the individual market

  • Locke Lord LLP
  • -
  • USA
  • -
  • January 3 2008

In the last several years, the media, and the California Departments of Managed Health Care and Insurance, as well as a number of prominent plaintiff attorneys have taken a keen interest in health plan and health insurer practices of rescinding individual policies

Federal district court dismisses PIP class action suit

  • Locke Lord LLP
  • -
  • USA
  • -
  • January 2 2008

In Shenandoah Chiropractic, P.A. v. National Specialty Ins. Co., 2007 WL 4276531 (S.D. Fla. Dec. 3, 2007), the United States District Court for the Southern District of Florida recently dismissed a class action complaint, seeking declaratory relief and alleging breach of contract in relation to a claim for Personal Injury Protection (“PIP”) benefits

Florida regulators reach settlement with Universal Health Care Insurance Company

  • Locke Lord LLP
  • -
  • USA
  • -
  • January 2 2008

Florida's Office of Insurance Regulation (OIR) has announced that it has settled its differences with Universal Health Care Insurance Company (UHCIC) through a consent order

Florida no-fault statute returns after short hiatus

  • Locke Lord LLP
  • -
  • USA
  • -
  • January 16 2008

After a three-month break, effective January 1, 2008, Florida returned to a no-fault system and again mandated that Florida drivers carry personal injury protection (“PIP”) coverage

Health insurers’ motion to treble damages against pharmaceutical companies in antitrust case is granted

  • Locke Lord LLP
  • -
  • USA
  • -
  • February 7 2008

On June 1, 2005, after a jury trial lasting over three weeks, a jury found for Blue Cross Blue Shield of Massachusetts (“BCBS-MA”), Blue Cross Blue Shield of Minnesota (“BCBS-MN”), Federated Mutual Insurance Company (“Federated”), and Health Care Service Corporation (“HCSC”) (collectively “Plaintiffs”) against Mylan Laboratories Inc. and Mylan Pharmaceuticals Inc., Cambrex Corporation, and Gyma Laboratories (“Defendants”) on state law claims agreement in unreasonable restraint of trade; conspiracy in unreasonable restraint of trade; monopolization; and attempted monopolization in the Lorazepam active pharmaceutical ingredient (“API”) market, Lorazepam tablet market and in the Clorazepate API and tablet markets